Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
08 déc. 2021 09h32 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
06 déc. 2021 09h00 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
02 déc. 2021 09h15 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Global Light Activated Therapies Market 2021-2030: Over 635 Patents have been Filed/Granted in Past 3 Years
26 nov. 2021 05h28 HE
|
Research and Markets
Dublin, Nov. 26, 2021 (GLOBE NEWSWIRE) -- The "Global Light Activated Therapies Market: Distribution by Target Indications, Key Players and Geographies: Industry Trends and Global Forecasts,...
$712.91Mn by 2028 Photomedicine Devices and Technologies Market Size Lead by Photodynamic Therapy (5.3% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
24 nov. 2021 07h05 HE
|
The Insight Partners
New York, Nov. 24, 2021 (GLOBE NEWSWIRE) -- According to our new research study on Photomedicine Devices and Technologies Market Size, Share, Revenue, Growth, Trends, Forecast to 2028 - COVID-19...
Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021
23 nov. 2021 08h15 HE
|
Biofrontera Inc.
WOBURN, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial...
Biofrontera Kicks Off US Clinical Study Program for Ameluz®
16 nov. 2021 09h03 HE
|
Biofrontera Inc.
WOBURN, MA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced...
The light activated therapies market is anticipated to grow at an annualized rate of 27.7% till 2030, claims Roots Analysis
21 oct. 2021 09h30 HE
|
Roots Analysis
London, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal,...
Supervisory Board of Biofrontera AG renews Management Board appointment
23 juil. 2020 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today...
Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
14 janv. 2020 00h30 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced...